Evolving Treatment Strategies in Small Cell Lung Cancer - Episode 2

Impact of Disease Staging on Prognosis and Treatment in SCLC

June 26, 2023

Taofeek K. Owonikoko, MD, PhD, Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital, Jacob Sands, MD, Dana-Farber Cancer Institute, Konstantinos Leventakos, MD, PhD Mayo Clinic

Panel experts review disease staging for limited and extensive stage small-cell lung cancer and discuss the impact of staging on treatment selection.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Importance of Early Referral and Diagnosis in Small-Cell Lung Cancer

Now Viewing

EP. 2: Impact of Disease Staging on Prognosis and Treatment in SCLC

EP. 3: Evolving Role of Biomarkers in SCLC

EP. 4: Patient Scenario 1: Newly Diagnosed ES-SCLC With Presence of Hepatic and Brain Metastases

EP. 5: Expert Insights on First-line Treatment Strategies in SCLC

EP. 6: CASPIAN: Long-Term Follow-up Data and Potential Predictors for Treatment Outcomes

EP. 7: Combination Therapy Approaches With Chemotherapy and Immunotherapy in ES-SCLC

EP. 8: ADRIATIC Trial and Investigational Treatment Approaches for Limited-Stage SCLC

EP. 9: Patient Scenario 2: 1L Management of ES-SCLC Positive for Synaptophysin With a Ki-67 Score of 90%

EP. 10: Real World Data for Combination Strategies With Chemotherapy and Immunotherapy in ES-SCLC

EP. 11: Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy

EP. 12: Evolving Treatment Strategies for SCLC in the Second-Line Setting and Beyond

EP. 13: LAGOON and IMFORTE Trials: Data Updates and Expert Insights

EP. 14: 2L Dosing Considerations and Management Strategies for SCLC

EP. 15: Novel Treatment Approaches for SCLC and Future Perspectives